Real-world evidence from a European cohort study of patients with treatment resistant depression: Baseline patient characteristics

Heerlein, K.; Young, Allan H.; Otte, C.; Frodl, T.; Degraeve, G.; Hagedoorn, W.; Oliveira Maia, A. J.; Pérez Solà, Víctor; Rathod, S.; Rosso, G.; Sierra, Pablo; Morrens, J.; Van Dooren, G.; Gali, Y.; Perugi, G.

doi:http://dx.doi.org/10.1016/j.jad.2020.11.124

Real-world evidence from a European cohort study of patients with treatment resistant depression: Baseline patient characteristics

License

Citation

Heerlein K, Young AH, Otte C, Frodl T, Degraeve G, Hagedoorn W, Oliveira-Maia AJ, Perez Sola V, Rathod S, Rosso G, Sierra P, Morrens J, Van Dooren G, Gali Y, Perugi G. Real-world evidence from a European cohort study of patients with treatment resistant depression: Baseline patient characteristics. J Affect Disord. 2021;283:115-22. DOI: 10.1016/j.jad.2020.11.124

Abstract

Background: Treatment resistant depression (TRD; failure to respond to ≥2 treatments) affects ~20% of patients with major depressive disorder (MDD). Real-world data could help describe patient characteristics and TRD disease burden, to assess the unmet needs of TRD patients in Europe. Methods: This observational study collected data from adults with moderate to severe TRD initiating a new treatment for depression, according to local standards of care. At baseline, socio-demographic characteristics, medical history, prior and current treatments were recorded. Disease severity, health-related quality of life (HRQoL), functionality and productivity were assessed. Results: Overall, 411 eligible patients were enrolled across seven European countries. Mean (standard deviation [SD]) patient age was 51.0 (10.8) years; 62.3% were female. Long-term sick leave was reported by 19.0% of patients; 30.2% were unemployed. The mean (SD) duration of the current episode was 2.6 (3.9) years. At baseline, mean (SD) HRQoL scores for EuroQoL 5-dimension 5-level (UK tariff) and EQ-Visual Analog Scale were 0.41 (0.25) and 41.1 (18.7), respectively. The Work Productivity and Activity Impairment questionnaire demonstrated mean (SD) absenteeism of 57.0% (44.9%) and presenteeism of 54.7% (29.5%); mean (SD) overall work impairment was 60.5% (29.9%). Limitations: Key limitations are small cohort size, absence of a control group and generalizability to countries with different healthcare models. Conclusions: TRD patients had a high disease burden, low HRQoL and reduced function and productivity, with a substantial proportion unable to work. This demonstrates an unmet treatment need in TRD patients that, if addressed, could reduce the heavy personal and societal burden.